TECTONIC THERAPEUTIC, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
TECTONIC THERAPEUTIC, INC. (TECX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 771.60 thousand shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2022-03-17
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2019-12-31 was 0.00 shares.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2019-09-30 was 0.00 shares.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2019-06-30 was 0.00 shares.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2019-03-31 was 2.30K shares.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2021 was 771.60K shares.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2019 was 2.30K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2021-12-31 | 771.60K shares 10-K · filed 2022-03-17 | |||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | 0.00 shares derived: sum of 2 quarters · filed 2020-03-16 | 0.00 shares derived: sum of 3 quarters · filed 2020-03-16 | 2.30K shares 10-K · filed 2020-03-16 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 0.00 shares derived: sum of 2 quarters · filed 2019-11-07 | 2.30K shares 10-Q · filed 2019-11-07 | |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 2.30K shares 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | 2.30K shares 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |